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Accumulating genetic evidence indicates that the primate-speciﬁc gene locus G72/G30 is related to
schizophrenia: it encodes for the protein pLG72, whose function is still the subject of controversy. We recently
demonstrated that pLG72 negatively affects the activity of human D-amino acid oxidase (hDAAO, also related
to schizophrenia susceptibility), which in neurons and (predominantly) in glia is expected to catabolize the
neuromodulator D-serine. The D-serine regulation mechanism relying on hDAAO–pLG72 interaction does not
match with the subcellular localizations proposed for hDAAO (peroxisomes) and pLG72 (mitochondria). By
using glioblastoma U87 cells transfected with plasmids encoding for hDAAO and/or pLG72 we provide
convergent lines of evidence that newly synthesized hDAAO, transitorily present in cytosol before being
delivered to the peroxisomes, colocalizes and interacts with pLG72 which we propose to be exposed on the
external membrane of mitochondria. We also report that newly synthesized cytosolic hDAAO is catalytically
active, and therefore pLG72 binding—and ensuing hDAAO inactivation—plays a protective role against D-serine
depletion.
© 2011 Elsevier Inc. All rights reserved.
Introduction
Astrocytes release numerous molecules that can modulate
synaptic transmission and synchronize neuronal network activity.
One such signaling molecule is D-serine. This “atypical” neuromodu-
lator is produced through the isomerization reaction catalyzed by the
enzyme serine racemase (SR) from L-serine (Wolosker et al., 1999)
and degraded by the α,β-elimination reaction of SR and/or by
oxidative deamination catalyzed by the FAD-containing ﬂavoprotein
D-amino acid oxidase (DAAO) (Baumgart and Rodríguez-Crespo,
2008; Pollegioni et al., 2007; Pollegioni and Sacchi, 2010). D-Serine
binds to the “glycine site” of the N-methyl-D-aspartate subtype of
glutamate receptors (NMDAr), which, together with the glutamate
site, must be occupied for the receptor to operate. D-Serine plays key
roles in excitatory synaptic transmission and in several pathological
conditions and is important for a number of physiological processes
involved in neuronal plasticity (Martineau et al., 2006; Oliet and
Mothet, 2009; Schell, 2004).
Different studies indicated that D-serine levels are decreased in
schizophrenic patients (Bendikov et al., 2007; Hashimoto et al., 2003)
and D-serine greatly ameliorated the symptoms of schizophrenia when
administered together with conventional neuroleptics (Heresco-Levy
et al., 2005). Schizophrenia is a complexdisease: a collectionof signs and
symptoms of unknown etiology, primarily deﬁned by observed signs of
psychosis. At least 43 candidate genes associated with a risk for
schizophrenia have been identiﬁed, but individual effect sizes are
modest (Insel, 2010). Among the possible schizophrenia susceptibility
genes, polymorphisms, and haplotypes in the genes encoding for DAAO,
pLG72 and SR have been identiﬁed, reviewed in (Pollegioni and Sacchi,
2010). The human G72 gene encodes for pLG72, a protein present only
in primates, which interacts with human DAAO (hDAAO) in astrocytes
(Chumakov et al., 2002; Sacchi et al., 2008). We recently demonstrated
that in vitro pLG72 inactivates hDAAO (Molla et al., 2006a,b) and that
cellular concentrations of D-serine depend on expression of the active
form of this ﬂavooxidase. Therefore, we proposed a model for
schizophrenia susceptibility in which a decrease in pLG72 expression
yields an anomalously high level of DAAO activity and induces an
excessive decrease in the local concentration of D-serine (Sacchi et al.,
2008).Here, the subcellular localizationof hDAAOandpLG72 represents
a major concern: DAAO is a well-known peroxisomal enzyme targeted
to this compartment by the C-terminal PTS1 sequence (Arnold et al.,
1979; Moreno et al., 1999; Sacchi et al., 2008; Pollegioni and Sacchi,
2010). However, there is controversy concerning the subcellular
distribution of pLG72: it has been proposed as a mitochondrial protein
(Benzel et al., 2008; Kvajo et al., 2008), but in human cultured astrocytes
it showed a perinuclear and tubular distribution (Sacchi et al., 2008).
Indeed, only 5% of the latter cells displayed (cytosolic) overlapping
signals for pLG72 and hDAAO, with amean average of 8% colocalization.
These observations suggested that pLG72 interaction with hDAAO is
probably drivenby speciﬁc spatiotemporal stimuli,whose featureswere
elusive.
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In the present study we investigated the subcellular localization
and interaction of hDAAOwith pLG72 by using U87 glioblastoma cells
transiently or stably transfected with plasmids encoding for ﬂuores-
cent-tagged pLG72 and/or hDAAO. We solved the apparent discrep-
ancy between the different subcellular localization of the two proteins
and their putative interaction, enlightening the effect of this
interaction on D-serine metabolism.
Results
hDAAO and pLG72 (apparently) localize to different cellular compartments
The hDAAO–pLG72 interaction has been previously studied in
vitro by using different biochemical approaches (Chumakov et al.,
2002; Sacchi et al., 2008). We also demonstrated that fusion of the
GFP protein with hDAAO does not alter its biochemical properties
(Caldinelli et al., 2010). As native hDAAO, the EGFP–hDAAO is fully
active, binds one molecule of FAD per protein monomer (with a Kd of
7 μM), and interacts with pLG72, yielding a complex constituted by
two hDAAO homodimers and two pLG72molecules; indeed, the time
course for inactivation of the EGFP–hDAAO–pLG72 complex closely
resembles that observed for native hDAAO. To investigate subcellular
localization (and interaction) of hDAAO and pLG72 in depth, U87
glioblastoma cells were transfected with plasmids encoding for the
corresponding tagged proteins (see Supplemental Materials). U87
Clones stably expressing EYFP–hDAAO (U87 EYFP–hDAAO cells),
hDAAO–EYFP (U87 hDAAO–EYFP cells), or pLG72–ECFP (U87
pLG72–ECFP cells) were then isolated in D-MEM medium to which
G418 was added. Confocal microscopy shows that, in the U87
pLG72–ECFP clone, the signal corresponding to the expressed
pLG72–ECFP protein displays a peculiar “spaghetti like” distribution
around the nucleus (Fig. 1A). In contrast, the EYFP–hDAAO signal is
near a punctuate subcellular structure (Fig. 1B) and differs from the
(cytosolic) one observed for the U87 hDAAO–EYFP cells (in which
the C-terminal peroxisomal targeting signal -SHL of the over-
expressed protein is masked by the fused EYFP, Fig. 1C). Since
DAAO is known to be a peroxisomal enzyme (Arnold et al., 1979;
Moreno et al., 1999; Sacchi et al., 2008; Pollegioni and Sacchi, 2010),
we used U87 EYFP–hDAAO cells in the present study, in addition to
U87 pLG72–ECFP cells, as a cellular systemmodel. In order to exclude
an effect of the speciﬁc tag on the cellular distribution of the
overexpressed proteins, similar experiments were also carried out
using U87 cells stably expressing pLG72–FLAG and untagged hDAAO
proteins (panels D and E of Fig. 1). In these cells the signal
distribution of both proteins closely resembled that observed for
pLG72–ECFP and EYFP–hDAAO, respectively.
Expression of the full-length, ﬂuorescent fusion proteins in the
selected, stable clones was conﬁrmed by Western blot analysis. A
single band corresponding to EYFP–hDAAO (66.4 kDa) is detected in
U87 EYFP–hDAAO (Fig. 1F, lane 3, α-DAAO panel). A signiﬁcant
expression of the full-length pLG72–ECFP in the U87 pLG72–ECFP
clone (Fig. 1F, lane 5, α-GFP panel) is also apparent: in addition to the
46-kDa band of the pLG72–ECFP fusion protein, a ~28-kDa band
corresponding to the ECFP moiety was also detected.
Fig. 1. Expression of chimeric ﬂuorescent hDAAO and pLG72 proteins in stably transfected U87 glioblastoma cells (A–E). Confocal analysis showing distribution of the different
ﬂuorescent chimeric proteins (panels A–D) and untagged hDAAO (panel E) in selected U87 clones. pLG72–ECFP and pLG72–FLAG display a “spaghetti like”, perinuclear distribution
(A and D), while the punctuate localization of EYFP–hDAAO and untagged hDAAO (labeled using sheep anti-hDAAO and donkey anti-sheep Alexa 488 antibodies) indicate
internalization into organelles (B and E). The hDAAO–EYFP shows a diffused, cytosolic distribution since the PTS1 signal at the C-terminus of hDAAO is masked by EYFP (C).
F)Western blot analysis performed using rabbit anti-hDAAO and mouse anti-GFP antibodies conﬁrms expression of the different ﬂuorescent fusion proteins in transfected U87 cells.
The same amount of sample (corresponding to 5×104 cells) was loaded in each lane, as further conﬁrmed by using an anti-α-tubulin antibody as internal control (bottom panel).
hDAAO–EYFP (0.03 μg, lane 2) recombinant puriﬁed protein was used as positive control. The level of endogenous hDAAO and pLG72 in U87 control cells is below the detection limit
(≤0.005 μg for hDAAO and ≤0.025 μg for pLG72), see lane 1.
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Confocal analysis suggests that EYFP–hDAAO, as well as untagged
hDAAO, ismainly targeted to peroxisomes since the distribution of the
labeled PMP70 (70-kDa peroxisomal membrane protein) overlaps
with the ﬂuorescence signal corresponding to the ﬂavoprotein
(Fig. 2A, B). Moreover, pLG72–ECFP and pLG72–FLAG exhibit a
perinuclear, “spaghetti like” signal which largely colocalizes with a
speciﬁc mitochondrial marker (Fig. 2C, F): in contrast, no overlapping
signal distribution is observed using PMP70 or 58 K protein (Fig. 2D, E
and G) asmarkers of peroxisomes and Golgi apparatus compartments,
respectively. A clear colocalization was also observed for the pLG72–
ECFP andMitotracker Green FM dye, used as amarker ofmitochondria
(not shown). Therefore, this experimental evidence indicates that
EYFP–hDAAO and pLG72–ECFP fusion proteins show distinct cellular
localizations. Notably, we recently demonstrated that, in cultured
human secondary astrocytes, endogenous pLG72 showed a different,
punctuate signal pattern which colocalized with hDAAO to a minor
extent (b 10%) (Sacchi et al., 2008). Nonetheless, the experimental
evidence obtained here using the U87 human glioblastoma cell
systems expressing EYFP–hDAAO or pLG72–ECFP indicate that the
two fusion proteins are targeted to different cellular destinations,
similarly to that reported for COS7 cells transfected with pLG72
(Kvajo et al., 2008).
To further conﬁrm the subcellular localization of pLG72, mito-
chondriawere immunoprecipitated using anti-TOM22 (Translocase of
the Outer mitochondrial Membrane) antibodies and MACS® technol-
ogy. The immunoprecipitated fractions corresponding to U87 and U87
pLG72–ECFP cells were analyzed by Western blot using anti-GFP and
anti-ERAB (Endoplasmic Reticulum-associated Amyloid Beta-peptide-
binding, a marker of mitochondrial matrix) antibodies and detected a
speciﬁc pLG72 signal in the immunoprecipitated intact mitochondria
of U87 cells stably expressing pLG72, see Fig. 2H.
hDAAO “interacts” with pLG72 before being targeted to its ﬁnal
(peroxisomal) destination
In order to verify whether the hDAAO–pLG72 interaction is
dependent on a spatiotemporal stimulus (Sacchi et al., 2008), U87
pLG72–ECFP cells were transiently transfectedwith the pEYFP–hDAAO-
C3 expression vector and analyzed by confocal microscopy at different
time points upon transfection. After 24 h, the EYFP–hDAAO-associated
ﬂuorescence is spread throughout the cells (Fig. 3, panel A left) and is
more intense in the perinuclear region where it clearly colocalizes with
the signal corresponding to pLG72–ECFP. Over time, the ﬂuorescence
signal associated with EYFP–hDAAO shows a gradual compartmental-
ization of the chimericﬂavoprotein: at 72 h after transfection the typical
punctuate (peroxisomal) distribution of hDAAO is evident (bottom
panel in Fig. 3A left). Interestingly, no time-dependent change in hDAAO
signal distribution is observed in U87 cells transiently expressing
hDAAO–EYFP (i.e. the enzyme form lacking the exposed peroxisomal
targeting signal, see Supplementary materials). By comparing pLG72–
ECFP and EYFP–hDAAO signal distribution in cells at 72 h from
transfection colocalization is only marginal: the overexpressed ﬂavo-
protein is initially cytosolic and is targeted to peroxisomes at later
timepoints. The same trend in hDAAO localization and signal intensity is
also observed in control U87 cells transfected with the same construct
(Fig. 3B left) or with the pIRES–hDAAO vector for the expression of the
untagged ﬂavoprotein (Fig. 3A and B, right panels). The observed time
course of hDAAO peroxisomal import is similar to that observed for
other peroxisomal complex proteins, e.g. the peroxisomal amount of
human epoxide hydroxylase in CHO cells increased up to 72 h from
transient transfection (Luo et al., 2008). Furthermore, a different time
course of signal colocalization is apparent for U87 pLG72–ECFP cells
Fig. 2. Subcellular localization of hDAAO and pLG72 by immunostaining experiments in
U87 stably transfected cells. A–B) The EYFP–hDAAO and untagged hDAAO pattern
distribution clearly overlaps with PMP70 staining, indicating that the fusion protein is
largely present inside peroxisomes. C–G) A clear overlapping of pLG72–ECFP or the
pLG72–FLAG corresponding signal is observed when the cells are stained using a
mitochondrial marker (Mito), suggesting that pLG72 is, for the most part, targeted to
these organelles (see panels C and F). No signiﬁcant overlapping in signal distribution
was observed between the pLG72–ECFP or pLG72–FLAG signal and PMP70 (D and G) or
58 K (E) stainings, ruling out the presence of this chimeric protein in peroxisomes or
Golgi apparatus, respectively. Bar=3 μm. H) In U87 pLG72–ECFP cells the subcellular
localization of the chimeric protein has been further studied by immunoprecipitation
experiments using anti-TOM22 magnetical Microbeads and the MACS Technology.
Western blot analysis conﬁrmed the presence of pLG72–ECFP in the eluted
mitochondrial fraction: a speciﬁc anti-GFP signal is apparent in the immunoprecipi-
tated sample (lane 1, compared to the corresponding control using untransfected U87
cells in lane 2). The nearly complete isolation of intact mitochondria is veriﬁed by an
anti-ERAB antibody: the correspondent immunorecognition signal is detected in the
immunoprecipitated samples (lanes 1 and 2) as well as in the starting cell lysates samples
(lanes 5 and 6), but not in the recovered column ﬂow through fractions (lanes 3 and 4).
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transiently transfected with plasmids encoding for EYFP–hDAAO or
hDAAO–EYFP (Fig. 3C and Suppl. Fig. S2): the signal colocalization is not
signiﬁcantly altered up to 72 h in cells expressing cytosolic hDAAO–
EYFP, whereas for cells expressing EYFP–hDAAO this value decreases
from~39%at24 h to ~14%at72 h (Fig. 3C). Thegreatest level ofhDAAO–
pLG72 colocalization is observed when the amount of newly synthe-
sized EYFP–hDAAO in cytosol is maximal, before it targets peroxisomes.
The inferred cellular protein–protein interaction was further
veriﬁed by FRET analysis on U87 pLG72–ECFP cells transiently
transfected with the pEYFP–hDAAO-C3. In Fig. 4, pLG72–ECFP and
EYFP–hDAAO signal distribution is shown in CFP and YFP panels,
respectively, while the raw signal due to the energy transfer is
reported in FRET panels. The raw signals were corrected to remove the
bleedthrough generated by spectral overlap between donor (ECFP)
and acceptor (EYFP) under the FRET ﬁlter combination. The resulting
digitalized NFRET images are shown in the right column in Fig. 4
(NFRET panels), together with the average parameters calculated in
ﬁve different regions within each cell. At 24 h upon transfection, FRET
signals closely resemble those for pLG72–ECFP (see Fig. 4A). The
calculated NFRET value in different cells ranges between 0.408±
0.0073 and 0.463±0.0069 (mean±standard error, n=6), yielding to
a mean value of 0.436±0.00647 (mean±standard error, n=12) and
Fig. 3. The time course of EYFP–hDAAO and hDAAO subcellular localization shows that pLG72–ECFP and the newly expressed hDAAO “transitorily” colocalize in U87 pLG72–ECFP
cells transfected with pEYFP–hDAAO or pIRES–hDAAO. A) Confocal microscopy analyses were performed on U87 pLG72–ECFP cells transiently transfected with pEYFP–hDAAO-C3
(left panels) or pIRES–hDAAO (right panels) constructs and ﬁxed at different time points upon transfection. At 24 h after transfection (top panels), pLG72–ECFP ﬂuorescence pattern
largely overlaps with the signals corresponding to EYFP–hDAAO (left) and hDAAO (right), which are diffusely distributed in the cytosol throughout the cell; a signiﬁcant
colocalization signal is observed in both cases, as depicted in the merge panels. At 48 h (central panels), EYFP–hDAAO and hDAAO signals start to appear compartimentalized and a
decrease in the colocalizationwith pLG72–ECFP is apparent (see merge panels). The typical punctuate distribution of EYFP–hDAAO ﬂuorescence is observed at 72 h after transfection
together with a weak signal colocalization between pLG72 and hDAAO (bottom panels). Bar is 10 μm (5 μm in “merge” panels). To make easier signals comparison, EYFP–DAAO
ﬂuorescence is depicted in magenta (left panels). In pIRES–hDAAO transfected cells hDAAO is stained with a sheep anti-DAAO and a donkey anti-sheep Alexa546 conjugated
antibodies. B) U87 Control cells transiently transfected with the pEYFP–hDAAO-C3 (left) and the pIRES–hDAAO (right) constructs and analyzed at 24–72 h upon transfection show
the same trend in EYFP–hDAAO and hDAAO signal distribution as observed in U87 pLG72–ECFP transfected cells (see the corresponding panels in A). C) The time course of signal
colocalization between hDAAO and pLG72 is different for U87 pLG72–ECFP cells transiently transfected with EYFP–hDAAO (white bars) or hDAAO–EYFP (black bars) expression
vectors. The colocalization was determined from confocal microscopy ﬂuorescence images as reported in “inset” panels (n=5–10). The change in colocalization value for EYFP–
hDAAO and pLG72–ECFP is statistically signiﬁcant at both 48 h (*pb0.004) and 72 h (**pb0.001). In contrast, no statistically signiﬁcant modiﬁcation in the colocalization signal is
observed for hDAAO–EYFP.
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thus supporting the interaction between the two human proteins. In
order to avoid the possibility of false positive signals, two control
experiments were performed by transfecting EYFP in the U87 cell
line stably expressing pLG72–ECFP as well as by cotransfecting ECFP
with EYFP–hDAAO in the U87 cell line. Calculated NFRET values
give 0.0359±0.0053 and 0.0348±0.0096 (mean±standard error,
n=12), respectively, suggesting that the proteins of our interest do
not aspeciﬁcally interact with widespread expressed ECFP or EYFP.
Based on the mitochondrial localization of pLG72, see above and
(Benzel et al., 2008; Kvajo et al., 2008), we now suggest that pLG72
and hDAAO could (transiently) interact on the mitochondrial surface.
The calculated NFRET mean values are appreciably lower at longer
times (the decrease is statistically signiﬁcant between 24 and 48 h,
white bars in Fig. 4D): targeting peroxisomes of overexpressed
hDAAO decreased interaction with pLG72. A clear colocalization
between hDAAO and pLG72 is also apparent using the plasmid
encoding for cytosolic hDAAO–EYFP: notably, NFRET mean values
slightly increase between 24 and 48 h after transfection (black bars in
Fig. 4D) because this chimeric form of the ﬂavoprotein is not
competent in peroxisomal targeting.
To further substantiate the “transient” interaction between hDAAO
and pLG72, we analyzed the distribution time course for the
ﬂavoprotein in soluble (cytosolic) and unsoluble fractions of U87 or
U87 pLG72–ECFP cells transiently transfected with pEYFP–hDAAO-C3
plasmid by means of Western blot and activity assays. In U87 control
cells at 24 h from transient transfection 24.9±3.7% of EYFP–hDAAO
is present in the soluble fraction, a value statistically signiﬁcantly
higher than for cells simultaneously and stably expressing pLG72
(18.8±0.5%), see Fig. 5A, B (top panels). The amount of hDAAO in the
soluble fraction increases at longer times, reaching similar levels at
48 h after EYFP–hDAAO transfection for both U87 and U87 pLG72–
ECFP cells (35.5 vs. 36.3%, respectively). This experiment also
demonstrates that cytosolic hDAAO is active: a rough calculation
based on the amount of hDAAO (as estimated from Western blot
analysis) reveals that its speciﬁc activity is similar for soluble vs.
membrane-bound hDAAO. Indeed, the values at 24 h from transfec-
tion indicate that overexpressed pLG72 binds the newly synthesized
hDAAO, thus affecting the amount of hDAAO present in the cytosolic
fraction, an effect that is no longer apparent at longer times probably
because the binding ability of pLG72 is saturated.
Weﬁnally veriﬁed if pLG72-interaction alters the stability (half life) of
hDAAO at cellular level. We analyzed byWestern blot the time course of
hDAAO and pLG72 levels in U87 and U87 pLG72–ECFP cells transiently
transfected for EYFP–hDAAO and that have been treated or not with
cycloheximide (a potent inhibitor of protein synthesis) at 24 h from
transfection. The amount of hDAAO following EYFP–hDAAO transfection
is rather stable in U87 cells treated or not with cycloheximide (not
shown), while its amount decreases in U87 pLG72–ECFP cells upon block
Fig. 4. FRET analysis conﬁrms EYFP–hDAAO and pLG72–ECFP cellular interaction. U87 pLG72–ECFP cells were transiently transfected with the pEYFP–hDAAO-C3 construct. Cells
were analyzed at 24 h (A), 48 h (B), and 72 h (C) upon transfection by a ﬂuorescent microscope equipped with a CCD camera and a three-ﬁlter setup: CFP ﬁlter (exc.=430 nm, em.=
470 nm, CFP panel); YFP ﬁlter (exc.=500 nm, em.=535 nm, YFP panel); and FRET ﬁlter (exc.=430 nm, em.=535 nm, FRET panel). The raw images were corrected to remove
the contribution of the bleedthrough signal, yielding the NFRET signal distribution (NFRET panel). The NFRET parameters calculated in ﬁve different areas for each analyzed cell
(n=5–10) are reported ±SD (standard deviation) and indicate protein–protein interaction. D) The plot of the time course of NFRET mean values (±standard error) determined for
U87 pLG72–ECFP cells transiently expressing EYFP–hDAAO (white bars, n=6–13) or hDAAO–EYFP (black bars, n=5–8) shows that a decrease in signal colocalization is apparent at
shorter times with the previous enzyme form. The change in NFRET parameter was demonstrated to be statistically signiﬁcant for cells expressing EYFP–hDAAO at 48 vs. 24 h
(**pb0.001) and for cells expressing hDAAO–EYFP at 72 vs. 48 h (*pb0.015).
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of protein synthesis (Fig. 6A, left). Concerning U87 pLG72–ECFP cells, a
quick decrease in pLG72 concentration is apparent upon block of protein
synthesis (Fig. 6B, right). From the cycloheximide-treatment results, we
conclude that the binding of a short-life protein such as pLG72 might
(negatively) affect the half life of (cytosolic) hDAAO.
Cellular D-serine levels
We analyzed the time course of D-serine concentration on U87 and
U87 pLG72–ECFP cells transiently transfected for EYFP–hDAAO. As
depicted in Fig. 6A, both the D-serine concentration and the D-/L-serine
ratio are signiﬁcantly higher in cells stably expressing pLG72 (5.8 vs.
4.2%), thus further conﬁrming the inhibitory effect of this protein on
hDAAO activity (Sacchi et al., 2008). The time course of D-serine
concentration following hDAAO transient expression is different in U87
control vs. U87 pLG72–ECFP cells, as is the D-serine concentration at
24 h (Fig. 6B): the binding of pLG72 to newly synthesized hDAAO
decreases the ﬂavooxidase activity and limits the decrease in D-serine
concentration. However, similar D-/L-serine ratios (~2%) are observed at
times ≥72 h for both cell systems: this observation indicates that this
value at the cellular level is controlled by further enzymatic activities
(i.e., by the SR activity that reversibly converts D- and L-serine).
Discussion
In neurobiology the existence (and role) of gliotransmission is the
subject of important debate (Smith, 2010). On one side of the argument,
D-serine is considered a “new” neuromodulator released by glial and
neuronal cells following stimulation of AMPA/kainate receptors by
glutamate released from neurons (Martineau et al., 2006; Oliet and
Mothet, 2009). Cellular concentrations of D-serinedependonboth SRand
DAAO enzymatic activity. While different mechanisms regulate brain SR
(Baumgart and Rodríguez-Crespo, 2008; Pollegioni and Sacchi, 2010),
less is known about hDAAO. Recently, we demonstrated in vitro that
pLG72 interacts with hDAAO to yield an ~200-kDa complex and a faster
enzyme inactivation (Sacchi et al., 2008). By transiently transfecting
human U87 glioblastoma cells with expression vectors encoding for
EGFP-tagged hDAAO or pLG72 proteins we showed that hDAAO has a
major role in controlling cellular D-serine levels and conﬁrmed the
proposal that in vivo pLG72 acts as an endogenous negativemodulator of
hDAAO (Sacchi et al., 2008). Indeed, this work identiﬁed hDAAO and
pLG72 in the same astrocytes of the human cerebral cortex and,
concerning the subcellular localization of hDAAO and pLG72, showed
that only5%of the cells displayedoverlapping signals (Sacchi et al., 2008).
This result suggested that pLG72 interaction with hDAAO is probably
driven by speciﬁc, unknown spatiotemporal stimuli.
By means of immunohistochemistry and organelle immunopre-
cipitation we have now conﬁrmed that pLG72 has a mitochondrial
localization, as previously reported for COS7 transfected cells and for
glioma U251 and primary neurons (Benzel et al., 2008; Kvajo et al.,
2008). However, a vescicular distribution of mitochondria in G72-
transfected cells, a modiﬁed morphological pattern related to
mitochondrial fragmentation (Kvajo et al., 2008), was not apparent
in U87 pLG72–ECFP cells. The discrepancy between our results and
Fig. 5. Cellular relative distribution of EYFP–hDAAO in transiently transfected U87 and U87 pLG72–ECFP cells. A) Western blot analysis shows that in U87 pLG72–ECFP cells the
amount of EYFP–hDAAO in the cytosolic subcellular fraction is lower than in U87 control cells at 24 h after transfection. The presence of intact organelles in the membrane fraction is
veriﬁed through the detection of anti-PMP70, anti-catalase (for peroxisomes), and anti-ERAB (for mitochondria) immunorecognition signals in the different samples. Lanes 1–3:
EYFP–hDAAO standard protein (0.015, 0.03, 0.045 μg, respectively). Lanes 4–5 and 6–7: EYFP–hDAAO transfected U87 and U87 pLG72–ECFP cells, respectively. M=membrane
fraction; C=cytosolic fraction. For sake of comparison, in each lane the same amount of total proteins (60 μg) was loaded, which corresponds to the following amounts of cells: U87
cells at 24 h, M=3.0×105 cells and C=9.8×105 cells; U87 pLG72–ECFP cells at 24 h, M=1.7×105 cells and C=5.2×105 cells; U87 cells at 48 h, M=1.0×105 cells and C=3.8×105
cells; U87 pLG72–ECFP cells at 48 h, M=1.3×105 cells and C=3.2×105 cells. B) Relative amount of hDAAO present in the soluble fraction of U87 cells (white bars) and U87 pLG72–
ECFP cells (gray bars) transiently transfected with EYFP–hDAAO. The data are the average (±standard deviation) of values determined fromWestern blot analysis (see also panel A)
and Amplex Red activity assay (determined using 7.5×105 cells). At 24 h, *pb0.001.
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those from (Kvajo et al., 2008) could arise from the different chimeric
pLG72 proteins used, although in both cases the tag was added at the
C-terminus of the protein to preserve the N-terminal end that
contains the putative mitochondrial targeting sequence. A possible
warning that the myc-tagged pLG72 conformation has been altered
(Kvajo et al., 2008) as compared to the native one is made apparent by
the failure to coimmunoprecipitate the hDAAO–pLG72 complex from
cotransfected COS7 cells and to inhibit cellular hDAAO following
exogenous myc-pLG72 expression. Our results, based on U87 cells
stably expressing pLG72 and transiently transfected with hDAAO,
demonstrate that colocalization of the two proteins is transitory. The
colocalization is most apparent at 24 h after hDAAO transfection,
when the ﬂuorescence signal corresponding to the ﬂavoenzyme is
largely diffused in cytosol while the associated FRET signal shows a
distribution pattern closely resembling the one typically associated
with mitochondria and pLG72. At this time the amount of hDAAO in
the membrane-bound fraction is higher in cells overexpressing pLG72
than in U87 control cells (Fig. 5), suggesting sequestration of newly
synthesized hDAAO on the surface of mitochondria because of pLG72
interaction. The pLG72–hDAAO colocalization is lost later, in con-
junction with a punctuate distribution of hDAAO, indicating that the
ﬂavoprotein has been correctly targeted to peroxisomes.
As stated by (Verrall et al., 2010) “the subcellular distribution of
DAAO is relevant to the question of how it ‘sees’ its substrates. For DAAO
located outside the peroxisomes, accessibility of DAAO to its substrates
would likely not be an issue”. The present work does not clarify the
origin of the spatiotemporal stimulus that induces the interaction
between pLG72 and hDAAO, but clearly shows that the newly
synthesized hDAAO interacts with pLG72. Indeed, we demonstrate
that cytosolic hDAAO is active and its speciﬁc activity resembles that
of the peroxisomal enzyme, and that under the experimental
conditions used a short-life protein such as pLG72 negatively affects
the half life of hDAAO (Fig. 6A). Since peroxisomal proteins are known
to acquire a conformation close to the ﬁnal one in the cytosol before
being targeted to their ﬁnal destination (peroxisomes are capable of
importing folded proteins and mature oligomers), pLG72 binding to
hDAAO on the cytosolic side of mitochondrial membranes (and
ensuing enzyme inactivation and faster degradation) plays a
protective role against DAAO-induced depletion of cytosolic D-serine
(Fig. 6) and in case of cellular oxidative stress.
In conclusion, since hypofunction of the NMDAr has been
implicated in the pathophysiology of schizophrenia, these receptors
represent a promising therapeutic target for psychiatric illness, see
(Labrie and Roder, 2010). Compounds that directly activate the
glycine/D-serine site of NMDAr or inhibit glycine transport have
demonstrated beneﬁcial effects in preclinical models and clinical
trials. Future pharmacological approaches for schizophrenia treat-
ment may involve targeting enzymes that affect D-serine metabolism,
and thus the processes underlying hDAAO regulation (e.g., the
elucidation of mechanisms of protein expression/degradation, the
post-translational modiﬁcations that affect its functionality, as well as
further binding partners, etc.) related to speciﬁc cellular scenarios will
need to be fully elucidated.
Experimental methods
Molecular cloning
The pEGFP–hDAAO-C3 construct (Sacchi et al., 2008) was used as a
template for subcloning hDAAO cDNA into the pEYFP-C3 and pEYFP-
N1 mammalian expression vectors (Clontech Laboratories): in this
way hDAAO can be expressed upstream and downstream of the
enhanced yellow ﬂuorescent protein (EYFP). The cDNA encoding for
pLG72 was purchased as a full ORF clone from imaGenes (IRAM-
p995E0829Q) and subcloned in pECFP-C3 and pECFP-N1 plasmids,
allowing pLG72 to be expressed upstream and downstream of the
enhanced cyan ﬂuorescent protein (ECFP), respectively. The latter
construct was used as a template for subcloning pLG72 cDNA into the
pCMV-SC-CF vector (Strataclone Mammalian Expression Vector
System, Stratagene), designed for high-level expression of epitope-
tagged proteins: three copies of the FLAG (DYKDDDDK) epitope were
fused to the C-terminal of the overexpressed pLG72. Indeed, hDAAO
cDNA was subcloned in the pcDNA3 (pcDNA3–hDAAO, Invitrogen)
Fig. 6. Effect of the overexpression of EYFP–hDAAO on hDAAO, pLG72 and D-serine
cellular levels in transiently transfected cells. A) U87 pLG72–EGFP cells transiently
transfected with pEYFP–hDAAO (at 24 h) were treated with (circles) or not (squares)
100 μg/mL cycloheximide (CHX) at time zero. Cells were harvested at the times shown,
separated by SDS-PAGE and immunoblotted. Values are the average±standard
deviation (n=4), normalized to actin. Left panel: immunorecognition using anti-
DAAO antibodies; right panel: immunorecognition using anti-GFP antibodies, to detect
pLG72. B) HPLC analysis of D- and L-serine concentrations in transiently transfected U87 and
U87 pLG72–ECFP cell extracts at different times upon transfection. D-serine and L-serine
levels in the transfected cells (gray bars) are compared to those detected in control cells
(U87 and U87 pLG72–ECFP untransfected cells respectively, black bars). The measured
levels of both enantiomers and the calculated D-serine/L-serine ratio are higher in U87
pLG72–ECFP, conﬁrming the negative effect on hDAAO activity proposed for pLG72–ECFP.
*pb0.005; ** pb0.001; *** pb0.0001. C) Western blot analysis conﬁrms the expression of
EYFP–hDAAO protein both in U87 (lanes 1, 3, 5) and U87 pLG72–ECFP cells (lanes 2, 4, 6),
and allows an estimation of the cellular level of the chimeric protein (an equal amount of
sample—corresponding to5×104 cells—has been loaded): themaximumlevel of expression
is observed at 48 h and a similar amount of EYFP–DAAO is expressed in the two cell types at
different times upon transfection. Lane 7: U87 control cells.
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and pIRESneo3 (pIRES–hDAAO, Clontech Laboratories) expression
vectors, in order to produce the untagged ﬂavoprotein.
Cell culture and transfection
The U87 human glioblastoma cells (ATCC) were maintained in
DMEM supplemented with 10% fetal bovine serum, 1 mM sodium
pyruvate, 2 mML-glutamine, penicillin/streptomycin, and amphotericin
B (Euroclone) at 37 °C in a 5% CO2 incubator as reported in (Sacchi et al.,
2008) and transfected using the FuGENE HD transfection reagent
(Roche) and 2 μg of pEYFP–hDAAO-C3 or -N1, pECFP–pLG72-C3 or -N1,
pcDNA3–hDAAO, pIRES–hDAAO or pLG72–FLAG constructs. Protein
expression levels were monitored either by using a ﬂuorescence
microscope (Olympus IX51) equipped with a FITC ﬁlter to detect the
emission signal associated with the ﬂuorescent tag, or by Western blot
analysis using anti-FLAG, anti-EGFP, or anti-hDAAO speciﬁc antibodies.
The transfected cells were used for further experiments or to select
stable clones, adding 0.4 mg/mL G418 to the growth medium.
Cellular D- and L-serine levels were determined as stated in (Sacchi
et al., 2008). Brieﬂy, 2.5×105 cells of U87 and U87–pLG72–ECF cells
transiently transfected with EYFP–hDAAO expression plasmid were
resuspended in 1 mL of ice-cold 5% trichloroacetic acid, sonicated, and
centrifuged for 45 min at 13,000 rpm. The soluble fraction was
extracted with water-saturated ether, neutralized, and derivatized
with o-phthaldialdehyde/N-acetyl-L-cysteine in borate buffer. D- and
L-serine were resolved by HPLC chromatography on a 5-μmWaters C8
(4.6×250 mm) reversed-phase column; amounts were determined
using a calibration curve obtained with standard D- and L-serine. The
analyses were replicated ﬁve times for each condition and statistical
analyses were performed using Kaleidagraph software (Synergy
Software). Variation between groups was evaluated by one-way
ANOVA, and post-hoc signiﬁcance tests were performed using a
Student's t test. Signiﬁcance was assessed at pb0.05.
Subcellular fractionation
A cytosolic cellular fraction (containing soluble proteins) and an
insoluble fraction enriched in proteins bound to membranes or
located inside organelles were prepared by differential centrifugation
(Graham, 2001). Brieﬂy, 1.2×107 cells were suspended in 0.4 mL of
homogenation buffer (10 mM Tris–HCl pH 8.0, 0.25 M sucrose),
protease inhibitors (2 μM leupeptin, 1 μM pepstatin, 500 μM PMSF),
40 μM FAD, 10 μg/ml DNAse, and 0.1% ethanol were added, and then
the preparation was homogenized with a Teﬂon potter. The
homogenate was centrifuged at 1000×g for 10 min at 4 °C; the pellet
was suspended in 0.4 mL of homogenation buffer and the previous
step was repeated; and the combined surnatants were then
centrifuged at 15,000×g for 25 min at 4 °C. The ﬁnal surnatant
(cytosolic fraction) and the combined pellets (membrane fraction)
were used for Western blot analysis and DAAO activity assay. DAAO
activity was measured by using the Amplex® UltraRed assay kit
(Invitrogen) based on the detection of H2O2 by the peroxidase-
mediated oxidation of the ﬂuorogenic Amplex UltraRed dye as stated
in (Sacchi et al., 2008). Brieﬂy, the cytosolic and the resuspended
membrane fraction were diluted 1:2 in the activity assay solution
containing 50 μM Amplex UltraRed, 0.2 U/mL horseradish peroxidase,
10 mM NaN3, 10 μM FAD, and 50 mM D-serine and incubated for
60 min at room temperature in the dark. The reactions were blocked
by adding 20 μL of Amplex UltraRed stop reagent and the ﬂuorescence
emission at 590 nmwas measured. For each sample a control without
the substrate D-serine was prepared: DAAO activity was expressed
as the difference in ﬂuorescence emission between sample and con-
trol assay mixtures. Statistical analyses were performed as reported
above.
Mitochondria isolation
A subcellular fraction enriched in intact mitochondria was
prepared from U87 and U87 pLG72–ECFP cells by using the MACS
Technology (Mitochondria isolation kit, Miltenyi Biotec) and mag-
netically labeling the organelles with an anti-TOM22 antibody. The
same experiment was also carried out on cells collected at 24 h from
transient transfection with pEYFP–hDAAO plasmid. Brieﬂy, 1.1×107
cells were collected and washed with 10 mL ice-cold PBS pH 7.2: the
cells were then resuspended in 1 mL ice-cold “lysis buffer” to which
was added protease inhibitors (2 μM leupeptin, 1 μM pepstatin,
500 μM PMSF), and the preparation was then homogenized by
passing it through a 0.2 μm needle 50 times. Then 9 mL of ice-cold
PBS and 50 μL of anti-TOM22 magnetic beads were added; this was
incubated for 1 h at 4 °C before magnetically separating the
mitochondria on the MACS column rinsed with “separation buffer”
and then placed in the MACS separator. The column was washed with
3×3 mL of separation buffer and removed from the separator. The
magnetically labeled mitochondria were ﬂushed out by adding 1.5 mL
of separation buffer.
Immunoblot and immunoﬂuorescence
Both stable and transiently transfected cells were resuspended in
SDS-PAGE sample buffer to reach 2500 cells/μL and 20 μL of each
sample was subjected to SDS-PAGE electrophoresis and Western blot
analyses (Sacchi et al., 2008). The polyvinylidene diﬂuoride mem-
branes (Immobilon-P, Millipore) were incubated 2 h at room
temperature or overnight at 4 °C in a blocking solution containing
4% dried milk in Tris-buffered saline (TBS; 10 mM Tris–HCl, pH 8.0,
0.5 M NaCl) to which 0.1% Tween-20 (TTBS) was added and then
incubated for 1.5 h at room temperature with primary antibodies.
Membranes were then washed extensively in TTBS containing 2%
dried milk and incubated for 1 h at room temperature with speciﬁc
peroxidase-conjugated immunoglobulins. The immunoreactivity sig-
nals were detected by enhanced chemiluminescence (ECL plus, GE
Healthcare) using the following primary antibodies: rabbit polyclonal
anti-hDAAO (1:5000, Davids Biotecnologie); mouse monoclonal anti-
GFP (1:200), mouse monoclonal anti-ERAB (1:500), and goat
polyclonal anti-α-tubulin (1:200), all from Santa Cruz Biotechnology;
rabbit polyclonal anti-catalase (1:5000, Abcam); rabbit polyclonal
anti-PMP70 and anti-actin (1:200, Sigma).
To investigate the stability at the cellular level of hDAAO and
pLG72, U87 and U87 pLG72–ECFP cells were transiently transfected
with pEYFP–hDAAO as described above andwere treatedwith 100 μg/
mL cycloheximide 24 h after transfection. At different time points,
cells were harvested for Western blot analysis.
Immunostaining and confocal analyses were performed as stated
in (Sacchi et al., 2008). Brieﬂy, U87 cells were seeded on round glass
coverslips (2.5×105 cells each) and incubated for 24 h at 37 °C and 5%
CO2; subsequently the cells were extensively washed with PBS
(10 mM sodium phosphate dibasic, 2 mM potassium phosphate
monobasic, 137 mM NaCl, and 2.7 mM KCl, pH 7.4) and ﬁxed with
4% p-formaldehyde and 4% sucrose in 0.1 M sodium phosphate buffer,
pH 7.4, for 15 min at room temperature. Fixed U87 cells were
permeabilized and the unspeciﬁc binding sites were blocked by a 30-
min incubation at room temperature in PBS supplemented with 4%
horse serum and 0.2% Triton X-100. The coverslips were incubated
overnight at 4 °C with primary antibodies against speciﬁc markers of
subcellular compartments: rabbit polyclonal anti-PMP70 for peroxi-
somes (1:400, Sigma); mouse monoclonal anti-58 K Golgi protein
(1:200, from Abcam). Mitochondria were stained by using a speciﬁc
anti-mitochondria antibody (1:25, Millipore). The pLG72 signal
distribution was also conﬁrmed in U87 pLG72–FLAG cells by staining
with a rabbit polyclonal anti-FLAG antibody (1:25, Sigma). Untagged
hDAAO was labeled using a sheep anti-hDAAO polyclonal and afﬁnity
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puriﬁed antibody (1:20, from Rockland). Immunoreactivity was
demonstrated with goat anti-rabbit FITC (1:100), donkey anti-sheep
Alexa488 andAlexa546, donkey anti-rabbit Alexa 647 anddonkey anti-
mouse Alexa 546-conjugated antibodies (1:1000, Molecular Probes).
Immunostained coverslips were imaged using an inverted laser-
scanning confocal microscope (TCS SP5, Leica Microsystems), equipped
with a 63.0×1.25 NA plan apochromate oil immersion objective.
Confocal image stackswere acquired using the Leica TCS software (with
a sequential mode, if necessary) avoiding interference between each
channel and without saturating any pixel, as reported in (Sacchi et al.,
2008). Coverslips incubated omitting the primary antibodies were
analyzed as negative controls. For colocalization analysis, z-optical
sectionswere analyzedusing theLeicaSP5 software colocalization tools;
the variation between groups was evaluated by one-way Anova. The
pictures show z-stacks of ten consecutive optical sections.
FRET image acquisition, analysis, and calculation
Fluorescence imageswere acquired as reported in (Bossi et al., 2007)
with a Retiga 2000R CCD camera (QImaging) mounted on a Zeiss
Axiovert IM35 inverted microscope equipped with ﬂuar ×40 oil-
immersion objective (Zeiss). Excitation was obtained by a 150-W
xenon arc lamp; excitation ﬁlters were 430/25 nm for ECFP and
500/20 nm for EYFP. A double dichroic ﬁlter (86002 BS), an optosplit
image splitter (CAIRN Research) ﬁtted with a 495DCLP beam splitter,
and two emission ﬁlters at 470/30 nm and 535/30 nm were used to
capture the two images (for ECFP and EYFP, respectively) on the same
frame in the CCD chip. To minimize photobleaching effects an
electronically driven shutter was interposed between the excitation
ﬁlter and the dichroic mirror. All ﬁlters were from Chroma Technology
Images; images were acquired under identical conditions and analyzed
with Image pro Plus software (Media Cybernetics). NFRET images were
constructed using the three-ﬁlter set method, according to (Xia and Liu,
2001). Relative background images were subtracted and independent
thresholding was performed on the individual images to avoid image-
processing artifacts. Donor and acceptor ﬂuorescence bleedthroughwas
calculated from U87 cells stably expressing pLG72–ECFP or EYFP–
hDAAOalone and subtracted fromthe FRET image toobtain thenet FRET
(nF) image. The nF image was then normalized by dividing it by the
square root of the donor×acceptor product (Xia and Liu, 2001), yielding
the NFRET parameter. Control experiments were performed on U87
pLG72–ECFP cells transiently transfectedwith pEYFP–C3 (0.5 μg) vector
and on U87 cells cotransfected with pEYFP–hDAAO-C3 (2 μg) and
pECFP-N1 (0.5 μg) plasmids, 24 h upon transfection.
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